IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	€0.1630	-1.81%	16,376
07/26/07	€0.1660	-1.19%	5,302
06/26/06	€0.1680	-3.72%	28,936
05/26/05	€0.1745	-7.18%	34,179
04/26/04	€0.1880	-5.53%	26,787

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Real-time Euronext Paris Other stock markets 03:25:00 10/08/2026 pm IST			5-day change	1st Jan Change
0.1630 ^EUR	-1.81%		-18.09%	+22.56%

16/06	IntegraGen Enters Receivership Proceedings
28/05	IntegraGen to file for court-ordered receivership

Market Cap	9L 10.18L 8L 8L 14.19L 9.69Cr 14.41L 96.48L 37.87L 4.86Cr 38.23L 37.39L 16Cr	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-22.28L -25.76L -20.81L -19.09L -35.91L -25Cr -36.48L -2.44Cr -95.83L -12Cr -96.74L -94.63L -41Cr	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

16/06	IntegraGen Enters Receivership Proceedings
28/05	IntegraGen to file for court-ordered receivership
24/04	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
23/04	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/25/02	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/25/02	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/25/29	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/25/15	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/24/18	IntegraGen: losses reduced, share price soars
30/24/30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/24/18	IntegraGen Reports Sales Results for the First-Half of 2024	CI
01/24/01	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

02/25/02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/25/02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/25/29	IntegraGen: 2024 Annual Results	BU
16/25/16	IntegraGen : Inside Information / Information on annual revenues	PU
15/25/15	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

IntegraGen Share Price

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news : IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Course Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

16/06	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime
16/06	IntegraGen en procédure de redressement judiciaire
16/06	Le marché remet sa cape d'invincibilité
16/06	IntegraGen convertit sa procédure de sauvegarde en redressement judiciaire
15/06	IntegraGen annonce la conversion de sa procédure de sauvegarde en redressement judiciaire afin de poursuivre les discussions engagées avec des acteurs intéressés par ses activités

1 day	-1.81%
1 week	-18.09%
Current month	-12.37%
1 month	+6.89%
3 months	-31.51%
6 months	-5.51%
Current year	+22.56%

1 week	0.16	0.2
1 month	0.12	0.24
Current year	0.12	0.36
1 year	0.12	0.36
3 years	0.12	1.45
5 years	0.12	2.04
10 years	0.12	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	09/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	01/01/2023
Berengere Genin COO	Chief Operating Officer	-	01/01/2024

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	22/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	01/01/2021
François Blondel BRD	Director/Board Member	63	31/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	-1.81%	-18.09%	-42.40%	-88.72%	12.66L
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+5.64%	+10.46%	+104.34%	+284.13%	397.87Cr
VERACYTE, INC.	+2.32%	+1.94%	+72.52%	+76.46%	379.61Cr
IOVANCE BIOTHERAPEUTICS, INC.	+2.09%	+55.77%	+200.47%	-16.58%	287.18Cr
CAREDX, INC.	+4.20%	+6.82%	+290.06%	+376.43%	241.55Cr
BGI GENOMICS CO., LTD.	+4.99%	+4.72%	-23.42%	-33.97%	227.28Cr
FREENOME, INC.	+2.20%	0.00%	+5.49%	-	125.84Cr
SEEGENE, INC.	+0.70%	+7.43%	-3.83%	+27.31%	93Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.32%	-5.18%	+183.18%	-42.05%	93Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	+3.09%	+3.92%	-37.44%	-7.20%	53Cr
Average	+2.31%	+7.62%	+74.90%	+63.98%	189.89Cr
Weighted average by Cap.	+3.34%	+12.80%	+108.85%	+123.39%

	2019	2020
Net sales	82.8L 95.72L 77.32L 70.93L 1.33Cr 91Cr 1.36Cr 9.07Cr 3.56Cr 46Cr 3.59Cr 3.52Cr 150.95Cr	90L 1.04Cr 84.05L 77.1L 1.45Cr 99Cr 1.47Cr 9.86Cr 3.87Cr 50Cr 3.91Cr 3.82Cr 164.08Cr
Net income	-3L -3L -3L -2L -5L -3.13Cr -5L -31.21L -12.25L -1.57Cr -12.37L -12.09L -5.19Cr	-4L -4L -4L -3L -6L -4.13Cr -6L -41.09L -16.13L -2.07Cr -16.28L -15.92L -6.84Cr
Net Debt	-25.19L -29.12L -23.52L -21.58L -40.58L -28Cr -41.23L -2.76Cr -1.08Cr -14Cr -1.09Cr -1.07Cr -46Cr	-31.09L -35.94L -29.03L -26.63L -50.09L -34Cr -50.89L -3.41Cr -1.34Cr -17Cr -1.35Cr -1.32Cr -57Cr